Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375977 | 1.00 | MAPT (0.47) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL12287057 | 0.83 | MAPT (0.53) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL18784640 | 0.80 | GSR (0.50) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL24238131 | 0.76 | MEN1 (0.55) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL29375611 | 0.76 | MEN1 (0.55) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL12287705 | 0.76 | KMT2A (0.69) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL12287149 | 0.71 | MEN1 (0.53) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL14667981 | 0.70 | MEN1 (0.45) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL31615079 | 0.70 | HAT1 (0.69) | MAPTMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL12958670 | 0.70 | MEN1 (0.52) | MAPTMEN1KMT2AKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | claimed |
| WO-2020111325-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT | 국립암센터 | 2020-06-04 | — | — | WO | claimed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
| WO-2020111325-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ACTIVATION INHIBITOR OF PLK1 AS ACTIVE INGREDIENT | 국립암센터 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | PLK1, PLK2, PLK4 | MAPT 919/4885MEN1 2253/4885KMT2A 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.